Search

Search Constraints

You searched for: Author/Creator Zonder, Jeffrey A

Search Results

1. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Issue 1 (January 2021)

2. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Issue 10 (October 2020)

3. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Issue 2 (February 2023)

4. INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. (28th February 2019)